SmocMabTM: Fully Human AntibodyTransgenic Mice Tailored to YourAntigen in 3 Months

Who We Are

GenoBioTX is a well-known contract research organization (CRO) providing genetically engineered animal models, and preclinical drug discovery services to biopharmaceutical companies and life science researchers.

Our Services

Generate KO HOM mice in just 3 months

  • Provision of at least 3 F0 homozygous mice per project within 3 months
  • Comprehensive and detailed report
  • Immediate phenotype analysis and self or high homology antigen immunization

Intergrated antibody discovery platform

  • Preparation of antigen and KO mouse
  • Animal immunization and hit generation
  • Lead Characterization
  • Cell line Development and antibody manufacture

YouMabTM fully human antibody transgenic mouse

  • Fully human antibodies produced efficiently
  • No need for humanization process
  • High affinity and specificity achieved
  • Streamlined and reliable discovery platform for high homology antigens

Antibody evaluation

  • Antibody characterization
  • Well-validated animal models
  • In vivo efficacy study
  • PK/PD test
  • Toxicity evaluation

Why choose us

  • Choose us for our unmatched expertise in animal model generation and antibody discovery, backed by years of experience in biomedical research.
  • Our state-of-the-art technology and proven track record ensure precise, reliable results, helping you accelerate your research and development.
  • With a focus on quality and efficiency, we provide customized solutions tailored to meet the unique demands of each project.

    News Center

    2025.02.05

    Personal Human lmmune System Mice: Accelerating the Translation of lmmuno-therapies from Bench to Bedside

    Register Link: https://www.eventbrite.com/e/genobiotx-february-2025-webinar-tickets-1228646116609?aff=oddtdtcreator Date: Wednesday, Feb. 26th, 2025; 2:00 pm EST or 11:00 am PST Meet Our Speaker: Dr. Huang earned a Ph.D. in 2004 from the Institute of Zoology, Chinese Academy of Sciences, followed by a postdoctoral fellowship at Peking University Health Science Center (2004–2006). Dr. Huang has dedicated over 15 years to groundbreaking […]

    2024.11.01

    CCR8: the Next Promising Immune Checkpoint for Antitumor Drugs Development

    CCR8, as a novel immune checkpoint in tumor microenvironment, was hotly discussed during 2022 AACR conference. Since then, numerous prestigious pharmaceutical corporations have shifted their attention to CCR8, previously almost unknown. You may wonder why CCR8 gave rise to so strong interest of pharmaceutical industry. Just follow us to have a quick review of CCR8, […]

    Email Back to top